MALARIA VACCINES MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-2024
Malaria Vaccines Market OverviewMore than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest share of global malaria burden, with around 89% of malaria cases and 91% of malarial deaths in 2015. Such high impact of this life threatening disease is influencing governments across various countries, companies, investors, and non-profit organizations to contribute towards curbing spreading of this disease.
Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/37
Treatment therapies include Artemisinin-based combination therapies (ACTs), chloroquine, and primaquine. Recurrence of this disease can lead to drug resistance and in severe cases can prove fatal. Therefore, prevention is the major focus of government, researchers, and drug companies. The World Health Organization (WHO) estimates that increase in prevention control and other measures has led to 60% reduction in malaria mortality since 2000. High prevalence and preventive measures initiated by global and national organizations would favor growth of the global malaria vaccines market.
Mosquirix – the First Malaria Vaccine in the Global Malaria Vaccines Market
Most major drug manufacturers have been constantly striving to develop a vaccine for this deadly disease. Among the pioneers in this field is GlaxoSmithKline, which has been working towards developing a malaria vaccine since 1984. In collaboration with the non-profit PATH Malaria Vaccine Initiative and funding from Bill & Melinda Gates Foundation, GlaxoSmithKline developed the first malarial vaccine.
Mosquirix, also known as RTS,S, was in development for around 30 years, with an investment of around US$ 565 million. Bill and Melinda Gates Foundation contributed over US$ 200 million towards this project. Mosquirix received marketing approval from the European authorities in July 2015. However, the WHO has recommended examination of the vaccine in a pilot study before introduction on a large scale. The study is being carried out in Africa, and has received a funding of US$ 25 million from Gavi—a global Vaccine Alliance—bringing together public and private sectors towards a common goal. Successful trials will lead to global launch of Mosquirix and boost the malaria vaccines market size.
Significant Potential for Malaria Vaccines Market in Africa, Latin America and Asia
Malaria vaccine seems to be the best solution to prevent the spread of malaria, especially considering increasing number of drug resistance cases and high fatality reported. People use bed nets and indoor residual spraying (IRS) to fight against mosquito infestation. Therefore, there is immense opportunity globally for malaria vaccines among the demographic group most at risk—infants (23 million births annually), pre-adolescent and early adolescent girls, pregnant women in sub-Saharan Africa, and population in Asia, Latin America, Africa, and Oceania. Furthermore, risk of transmission of the disease increases from the ‘traveller’ and military population travelling from the U.S., Europe, Japan, and Australia, a malaria free zone to the highly prone emerging economies. The global malaria vaccines market dynamics are mainly shaped by major purchasers, namely healthcare and non-profit organizations.
Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/ongoing-insight/malaria-vaccines-market-37
Malaria Vaccines Market Future Outlook
Mosquirix is a great boon for population in the highly prone regions of malaria infection. However, accessibility and low cost of this vaccine is essential to serve the large population in the highly prone emerging economies. Sanaria Inc. is a biotechnology company which aims to develop and commercialize whole-parasite sporozoite vaccines against Plasmodium falciparum that causes 95% of malaria cases. Mymetics Corporation—a Switzerland-based vaccines developer—uses its virosome platform technology to develop vaccines. There are two vaccine candidates in its pipeline, of which one cleared the phase 1b clinical trail, while the other is in the preclinical stage. Moreover, use of new technologies such as Nucleic acid vaccines, Proteosomes, and several new adjuvants could lead to development of next-generation malaria vaccines.
Such global commitments will encourage investors around the world to contribute towards a global malaria eradication mission. Further, the malaria vaccines market outlook for future holds much promise, with new vaccines being developed mainly focused on improving effectiveness of products.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MALARIA VACCINES MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-2024 here
News-ID: 454449 • Views: …
More Releases from MALARIA VACCINES MARKET
Malaria Vaccines Market, Company Analysis and Forecast to 2024
Malaria Vaccines Market Overview
More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest…
Malaria Vaccines Market - Trends, Outlook, and Opportunity Analysis, 2016-2024
Malaria Vaccines Market Future Outlook
Mosquirix is a great boon for population in the highly prone regions of malaria infection. However, accessibility and low cost of this vaccine is essential to serve the large population in the highly prone emerging economies. Sanaria Inc. is a biotechnology company which aims to develop and commercialize whole-parasite sporozoite vaccines against Plasmodium falciparum that causes 95% of malaria cases. Mymetics Corporation—a Switzerland-based vaccines developer—uses its…
Malaria Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportu …
Malaria Vaccines Market Overview
More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest…
Malaria Vaccines Market – Global Industry Analysis 2024
Today nearly 40% of the global population is at risk of malaria. According to the World Health Organization (WHO), there were nearly 214 million malaria cases in 2015 and approximately 4,38,000 malarial deaths globally. More than 70% of these deaths occur in children under 5 years of age. The Sub-Saharan Africa carries the highest share of global malaria burden with nearly 89% of malaria cases and 91% of malarial deaths…
More Releases for Vaccine
Flu Vaccine (Influenza Vaccine) Market: A look into the future of the “Univers …
Latest update on Flu Vaccine (Influenza Vaccine) Market Analysis Report published with an SMI, the industry growth analysis, and Projection by 2021-2028. This report is highly predictive as it holds the overall market analysis of the topmost companies in the Flu Vaccine (Influenza Vaccine) industry. With the classified Flu Vaccine (Influenza Vaccine) market research based on various growing regions, this report provides leading players' portfolios along with sales, growth, market…
Vaccine Market
Rise in the prevalence of infectious diseases, increase in immunization programs across the globe, and surge in R&D activities to develop new vaccine drive the growth of the global vaccine market.
Global Vaccines Market was pegged at $32.46 billion in 2019, and is anticipated to hit $54.15 billion by 2027, registering a CAGR of 6.6% from 2020 to 2027. The report provides an in-depth analysis of the top investment pockets, top…
US Flu Vaccine [Influenza Vaccine] Market Research Report 2020
DPI Research offers a latest published report on “Influenza Vaccines in the United States – Market Size, Trends, Opportunities and Growth Potential” delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key US flu vaccines market players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze…
Measles Vaccine
Measles Vaccine Market describes its growth, size, share, Forecast and trends to 2025
Measles Vaccine Market Production and Demand Analysis 2019 to 2025
Measles Vaccine Market 2019 Manufacturing Analysis and Development Forecast 2025
Measles Vaccine Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Measles Vaccine Market to Insight By 2025: Top Key Vendors
The global Measles Vaccine market is valued at million US$ in 2018 and will reach million US$ by the…
Monovalent vaccine segment to accumulate maximum Paediatric Vaccine Market share
According to a new report published by Future Market Insights titled “Paediatric Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026”, in terms of revenue, the global paediatric vaccine market is expected to increase at 12.2% CAGR during the forecast period 2016-2026. The global paediatric vaccine market is expected to reach US$ 27.97 Bn in 2016.
Paediatric vaccine market is a billion dollar market accounting for a substantial proportion…
Key Tools for Innovative Vaccine Designs: Vaccine Adjuvants
The report “NORTH AMERICA VACCINE ADJUVANTS MARKET” provides the detail description of market segmentation, applications, growth, size, and outlook. The market is projected to reach USD $278 Million by 2024, at a CAGR of 11.3%.
An adjuvant is an immunological agent, which modifies the effect of other agents. Adjuvants can also act as an irritant, which engages and amplifies the body immune response. Adjuvants are added to vaccines to boost the…